Evogene Co, 'When Biology Meets Disruptive Technologies,' Confirms Earnings Results Release Date

Loading...
Loading...

Computational biology company Evogene Ltd. EVGN  will release its financial results for the full year and fourth quarter of 2021 on March 10, 2022. On the day of the announcement, the company's management will host a conference call to discuss the results at 09:00 a.m. EST.

Evogene established three unique technological engines, MicroBoost AI, ChemPass AI and GeneRator AI. Each technological engine is focused on the discovery and development of products based on one of the following core components: microbes (Microboost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). The company uses its technological engines to develop products through subsidiaries and with strategic partners. Evogene's main subsidiaries utilize the technological engines to develop novel products as follows: human microbiome-based therapeutics by Biomica Ltd., medical cannabis by Canonic Ltd., ag-chemicals by AgPlenus and ag-biologicals by Lavie Bio Ltd

Price Action

Evogene shares traded 1.63% higher at $1.25 per share at the time of writing Tuesday morning.

 

Posted In: CannabisNewsPenny StocksMarketsAgPlenusBiomicaCanonicLavie Bio
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Benzinga Cannabis Capital Conference is coming to Florida

The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

Get your tickets now on bzcannabis.com – Prices will increase very soon!


Loading...